Clinical Trials Logo

Clinical Trial Summary

This prospective study will take place at Hotel Dieu de France hospital in Lebanon. One hundred children undergoing cardiac surgery for congenital heart disease between May 2020 and May 2021 will be included. After obtaining the informed consent of the parents, demographic and surgical information will be collected. Serum creatinine, lactic acid, urinary neutrophil gelatinase-associated lipocalin marker (NGAL), and oxygen (O2) saturation will be measured before the operation. A pediatric NIRS sensor will be placed on the right side below the costo-vertebral angle overlying the right kidney and continuous regional oxygen saturation (rSO2) will be recorded every 5 to 10 minutes throughout the operation until 24 hours after surgery. The children will be divided into 2 groups; 50 each. Grp 1: No clinical intervention was performed based on NIRS values. Grp 2: several maneuvers are performed such as an increase in cardiac output, temperature, hemoglobin to optimize the value of NIRS > 80%. All patients will receive standard standard care during the study period and continuous infusion of furosemide (0.5-1 mg / kg / 6 hours) within the first 24-48 hours postoperatively will be administered to all patients. Creatinine and lactic acid will be measured immediately postoperatively and then once a day until D2 and D7. The urinary NGAL marker will be dosed immediately postoperatively and then at 2h, 6h, 12h and 24h with hourly monitoring of diuresis and NIRS until 24h postoperatively.


Clinical Trial Description

This prospective study will take place at Hotel Dieu de France hospital in Lebanon. One hundred children aged 16 and under, undergoing cardiac surgery with cardiopulmonary bypass (CPB) for congenital heart diseases will be included between May 2020 and May 2021. The surgeries to be included will be the tetralogy of Fallot, transposition of the great arteries, ventricular septal defect, atrial septal defect and the atrioventricular canal defect. Any premature under 35 weeks of gestation, the presence of a genetic disease, an abnormal renal ultrasound, a preoperative renal failure with creatinine abnormal for age, or repeated urinary tract infections will be excluded from the study. After obtaining the informed consent of the parents, demographic information (age, weight, height, sex) will be collected.. Serum creatinine, lactic acid, urinary NGAL marker, and O2 saturation will be measured before the operation. A pediatric NIRS sensor will be placed on the right side below the costo-vertebral angle covering the right kidney and continuous rSO2 will be recorded every 5 to 10 minutes throughout the operation as well as with each change of situation, then every hour in pediatric resuscitation until 24 hours postoperatively. The children will be divided into 2 groups of 50 patients each; Grp 1: No clinical intervention will be performed based on the NIRS and Grp 2: several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%. Surgical information (cardiac pathology, surgical procedure, operating time, duration of CPB, duration of aortic cross-clamping, duration of circulatory arrest, intraoperative complications) will be collected. All patients will receive standard standard care during the study period. Patients will receive continuous infusion of furosemide (0.5-1 mg / kg / 6 hours) within the first 24-48 hours postoperatively. Postoperatively, the need for catecholamines, the hemodynamic stability according to the Vasoactive-Inotropic Score (VIS), the delay to extubation, the stay in intensive care, the complications that occurred and the need for recourse to the dialysis will be noted. Creatinine and lactic acid will be measured immediately postoperatively and then once a day until D2 and D7. The urinary NGAL marker will be dosed immediately postoperatively and then at 2h, 6h, 12h and 24h with hourly monitoring of diuresis and NIRS until 24h postoperatively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04605705
Study type Observational
Source Saint-Joseph University
Contact AFRIDA H GERGESS, M.D.
Phone 009613957831
Email gergessafrida@gmail.com
Status Recruiting
Phase
Start date September 23, 2020
Completion date September 2021

See also
  Status Clinical Trial Phase
Completed NCT03136315 - Evaluation of the Renal Function in an Ultra-endurance Race. N/A
Completed NCT02531724 - Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery Phase 4
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT03311256 - Determination of the "Tissue Transit Time" (TTT)
Terminated NCT02808052 - Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency Phase 1
Recruiting NCT03489759 - The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT N/A
Active, not recruiting NCT05384899 - Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol
Recruiting NCT05240833 - VExUS-guided Fluid Management in Patients With Acute Kidney Injury in the Intensive Care Unit N/A
Withdrawn NCT00855127 - New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients N/A
Suspended NCT00190034 - Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass. Phase 4
Completed NCT01233882 - Bosutinib In Subjects With Renal Impairment Phase 1
Active, not recruiting NCT00806039 - Impact of Early Renal Involvement on the Development of Severe In-hospital Renal Failure N/A
Terminated NCT00322933 - Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure N/A